Bmy stock forecast 2025 analysts note that the BMY stock

Analysts note that the BMY stock forecast 2025 is partially reliant on successful Phase III trials, which could expand its revenue base by nearly $1.2B annually if approvals materialize. The biopharmaceutical company's shares have seen a decrease of 16.53% over the last month, not keeping up with the Medical sector's loss of 7.47% and the S&P 500's loss of 4.17%. Bristol Myers Squibb stock was up 2.98% in pre-market trading on Thursday, following a 1.88% dip yesterday. The shares have also fallen 15.82% year-to-date and 4.55% over the past 12 months. Currency-neutral forecasts show BMY stock forecast 2025 retaining margin strength, even amid global FX shifts, keeping net income trajectories stable.